Biolidics

CoVid-19

Regulators keep watch as companies jump on Covid-19 bandwagon

SINGAPORE (Apr 30): At the beginning of the Covid-19 outbreak back in January, listed glove-makers experienced a surge in their share price as investors scurried to scoop up these counters.

CoVid-19

Singapore firm Biolidics to launch rapid test kit to detect Covid-19 within 10 minutes

SINGAPORE (Mar 30): Singapore-based medical technology firm Biolidics announced Monday it is launching a rapid test kit for Covid-19 that can detect the coronavirus within 10 minutes, with a claime

Equity raising

Biolidics issues 17.9 mil shares in placement exercise to raise $3.1 mil

SINGAPORE (Mar 16): Cancer solution specialist Biolidics is raising $3.13 million from a share placement exercise mainly to expand the group’s businesses.

Joint ventures and alliances

Biolidics enters into collaboration agreement with Genome Institute of Singapore

SINGAPORE (Sept 10): Biolidics has entered into an agreement with the Genome Institute of Singapore (GIS) to collaborate and develop a new and innovative liquid biopsy test in the field of circulat

Joint ventures and alliances

Biolidics in partnership to expand into China cancer diagnostics market

SINGAPORE (June 25): Medical technology company Biolidics has entered into a partnership with Zhongshan TopGene Medical Laboratory Co to develop and commercialise laboratory-developed tests (LDTs)

Broker's Calls

Biolidics started at 'add' with 32 cents target by CGS-CIMB on liquid biopsy market

SINGAPORE (Mar 27): CGS-CIMB is starting coverage of biotech firm Biolidics at “add” given it has developed a game-changing liquid biopsy kit for cancer.

IPO

Biolidics shares slump on Catalist debut

SINGAPORE (Dec 19): Just two hours into its debut on the Singapore Exchange (SGX) Catalist board, shares in medical technology firm Biolidics have slumped 23.2% from its listing price of 28 cents.

IPO

Biolidics selling 27.5 mil new shares at 28 cents each in conjunction with Catalist listing

SINGAPORE (Dec 11): Medtech company Biolidics is selling 27.5 million new shares at 28 cents each to retail and institutional investors in a private placement ahead of its listing on the Catalist B

IPO

Clearbridge Health associate Biolidics lodges prelim prospectus

SINGAPORE (Nov 26): Biolidics, a cancer diagnostic solutions developer and an associate company of Clearbridge Health, on Friday lodged a preliminary prospectus for a planned initial public offerin

Be informed of the stories that matter